Search

Your search keyword '"Cytomegalovirus immunology"' showing total 128 results

Search Constraints

Start Over You searched for: Descriptor "Cytomegalovirus immunology" Remove constraint Descriptor: "Cytomegalovirus immunology" Journal transplantation Remove constraint Journal: transplantation
128 results on '"Cytomegalovirus immunology"'

Search Results

1. Cytomegalovirus Infection Downregulates Vitamin D Receptor in Patients Undergoing Hematopoietic Stem Cell Transplantation.

2. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.

3. New Insights Into the Molecular Mechanisms and Immune Control of Cytomegalovirus Reactivation.

4. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.

5. Impact of CMV Reactivation, Treatment Approaches, and Immune Reconstitution in a Nonmyeloablative Tolerance Induction Protocol in Cynomolgus Macaques.

6. Enrichment of Cytomegalovirus-induced NKG2C+ Natural Killer Cells in the Lung Allograft.

7. Development of a Predictive Model Using Endoscopic Features for Gastric Cytomegalovirus Infection in Renal Transplant Patients.

8. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.

9. Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients.

10. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.

11. Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation.

12. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.

13. Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation.

14. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.

15. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.

17. Human Cytomegalovirus-Encoded Receptor US28 Is Expressed in Renal Allografts and Facilitates Viral Spreading In Vitro.

18. Cytomegalovirus-Specific T Cells Isolated by IFN-γ Secretion Assay Do Not Induce Significant Graft-Versus-Host Reactions In Vitro.

19. The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV.

20. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.

21. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.

22. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.

23. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.

24. A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients.

25. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin.

26. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling.

27. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.

28. Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.

30. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.

31. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.

32. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients.

33. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.

34. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.

35. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.

36. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.

37. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.

38. Human fibroblasts are permissive for porcine cytomegalovirus in vitro.

39. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.

40. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

41. Changes in coronary arterial dimensions early after cardiac transplantation.

42. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.

44. Gamma delta T cells and resolution of cytomegalovirus infection in an HIV/HCV coinfected patient after liver transplantation.

45. Cytomegalovirus-related complications in human hand transplantation.

46. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.

47. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules.

48. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity.

49. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.

50. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.

Catalog

Books, media, physical & digital resources